ArticleThe Lancet. Oncology2015

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

Josep Tabernero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.